The 2028 Patent Cliff And Other Fairy Tale

I remember sitting in a conference room at Merck’s (MRK) Kenilworth headquarters back in 2014, watching their presentations on some experimental cancer drug called pembrolizumab.

Half the analysts in the room were checking their phones. That drug became Keytruda, now pulling in $32 billion annually, and those same analysts are convinced the company’s about to fall off a cliff in 2028.

They were wrong then, they’re wrong now.

The latest quarterly numbers tell you everything you need to know about where this company actually stands.

Merck just reported $16.4 billion in sales with $2 per share in EPS, guiding for roughly $66 billion in 2026 revenue.

The stock’s up nearly 50% in six months, and suddenly everyone’s worried about valuation.

At 13 times forward earnings for a company with $22.3 billion in annual profit and a pharmaceutical pipeline worth $70 billion, we’re nowhere near expensive territory.

Keytruda’s 2028 patent cliff dominates every sell-side research note I read, as if the entire pharmaceutical industry hasn’t dealt with patent expirations since the dawn of time.

But here’s how the game actually works: Keytruda Qlex just got approved, and the permanent J-code they’re expecting in April isn’t some bureaucratic formality. It’s a moat-building exercise that makes it brutally expensive for biosimilars to dislodge them from hospital formularies.

I watched this exact playbook with AbbVie and Humira. The real revenue cliff doesn’t materialize for five to seven years after patent expiration, not two.

Keytruda’s going from $8.4 billion in quarterly revenue to maybe $6 billion by 2030, not zero.

Qlex will capture 40% of what generic competition would otherwise steal, and that’s a conservative estimate based on how hospital purchasing actually functions.

The vaccine portfolio is where Merck’s building something genuinely interesting.

Gardasil dropped from $1.9 billion to roughly $1 billion in quarterly sales, and everyone treats this like a crisis. Meanwhile, Capvaxive went from $50 million to $279 million in one quarter.

That’s 460% growth annualized to over $1 billion, and you don’t see those numbers in the vaccine space unless you’ve cracked something structural.

Hospital pharmacy buyers are desperate for alternatives to Pfizer’s Prevnar franchise, and Capvaxive covers more serotypes.

In the world of hospital purchasing, more coverage equals fewer headaches with insurance reimbursement. Merck’s not competing on price here; they’re competing on avoiding paperwork, which is infinitely more valuable.

The capital allocation machine is what separates Merck from every other big pharma name trading at similar multiples.

They’re guiding for $66 billion in revenue with $22.3 billion in profit after you strip out the Cidara acquisition charge.

They’re buying back $3 billion of stock, paying out $5 billion in dividends, and still writing $9 billion checks for acquisitions.

This is the pharmaceutical equivalent of Berkshire Hathaway’s float strategy, except instead of insurance premiums funding investments, it’s blockbuster drugs funding uncorrelated revenue streams.

The Cidara deal is particularly instructive if you understand how big pharma procurement cycles work. Wall Street sees a $9.2 billion charge and models forward earnings down 46% from 2025 to 2026.

What gets missed entirely is that Cidara’s antifungal pipeline doesn’t compete in the same hospital budget bucket as oncology drugs.

When hospital systems negotiate annual contracts, antifungals sit in completely different purchasing committees than cancer treatments. Merck’s buying uncorrelated revenue streams, which is exactly what you want when you’ve got a patent cliff looming.

It’s portfolio theory applied to pharmaceutical cash flows.

The dividend story is better than it looks on the surface. That 2.8% yield seems pedestrian until you realize they’ve been compound growing it at 7% annually while simultaneously retiring 1% of shares outstanding every year.

Over a decade, that’s a total return compounding machine wrapped in a pharma company’s balance sheet. The stock is trading at 13 times forward earnings after the 50% run, which would be expensive if we were still in a Fed tightening cycle.

But we’re heading into rate cuts, and healthcare names with recession-proof cash flows get re-rated to 18-20 times earnings in that environment. I’ve seen this cycle play out three times since 2000.

Merck’s pipeline shows $70 billion in total commercial opportunity through 2028, and the market’s giving them credit for maybe half of that.

Every time one of these late-stage assets gets approved early or shows better trial data, you get multiple expansions on top of earnings growth.

My number for Merck by the end of 2027 is $155, and I think we hit $140 by the end of this year. That’s arithmetic based on earnings power that’s already visible in the quarterly reports.

The 50% spike everyone’s worried about isn’t the end of the move. And when Merck crosses $150, those analysts who spent 2014 checking their phones will write research notes explaining why it was obvious all along.